London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Transfection is the process of deliberately introducing naked or purified nucleic acids into eukaryotic cells.
An ImmunoBody® is a DNA plasmid that encodes a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells. ... (a) Direct presentation: ImmunoBody® DNA targets antigen-presenting cells (APCs) directly via transfection.
it encodes ...
BIOCHEMISTRY
(of a gene) be responsible for producing (a substance or behaviour).
Ray what you need is "plasmid dna delivery" in your searches
One aspect of nano-delivery that interests me is targeted delivery.
Here's an article that describes one type of targeting
https://www.spandidos-publications.com/ijo/52/2/389
"In order to improve the specificity of nanocarriers, targeting ligands may be attached to their surface via a PEG spacer arm. The targeting ligands, which are attached to the distal end of the spacer arm on the surface of nanocarriers, facilitate access of the carrier to the targeted site of interaction (3). Delivery of nanoparticle involving the use of peripherally-conjugated targeting moieties is known as active targeting. Active targeting is a promising tool for the treatment of cancer due to its ability to increase therapeutic effectiveness and reduce potential side effects. "
So nano-delivery does not open up the target cells in the same way that Trigrid does. However, by attaching ligands to the nano-particle it may be more efficient in reaching the correct target. This is, I believe, why it can match and possibly surpass the efficiency of Trigrid.
In addition it protects the vaccine from degradation.
so from that link you can see everything as a mathematical optimal calculation
so Trigrid equation 1 ... worked
why would you change that ... ?
you cannot improve on "cross presentation" to the Dendritic cell ... scancell has the optimal delivery ... nanovesicle allows a higher dose ... with a similar "quality" delivery because it has no operating electric field which restricts the amount of cells that can be "opened"
Last AGM Lindy gave an exciting talk about MODi2. I wasn't there but you could tell from Steve's recording just how excited she was about it.
To me, Lindy's talk is always the highlight of the AGM.
This year's subject ?
Gylcans?
More development of Modi2?
More on combination of Modi1 and Modi2?
Details of the nano-delivery chosen for SCIB2?
they are as i have explained on the other BB .. the syringe is compatible to both, and that cartridge contains the tri grid arrangement in the mark 1 and 2 "the pulse" is so precise that no variation in that is permissible ... so the setup is critical which is why the commercial product i believe removes operator error ... rather than changes the "parameters" this is IMHO
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814886/
Which could spark the question of whether the two sets of data with Tri Grid are admissable??
Interesting one, enjoyed the conversation , take care Inan. ATB
point being we have the license off ichor .. deal is done .. so really for Ichor to profit from that ... they need to sort out the FDA
i am not worried about Ichor because we have the mark 2 SCIB1 ... which could start a fresh trial using nanovesicle and double the patient population we could reach ..
I was a big fan of Hampshire most of my life and used to see them when i lived in Bournemouth, Barry Richards and Gordon Greenidge opening batsmen, what would they have only achieved in the one day game now, which is what I prefer or the half hour highlights in the evening.
Anyway buddy, interesting conversation, what do you think ofwhat i said about Ichor?? Just to close.
because the world cup was so interesting got a taste for it ... and the complexity of a test is far more intriguing that a one day game, never really followed cricket, now i have the twists and turns are fascinating because it really is a "test" and to face a 95 mph 5 oz weight which you can really only see in slow motion just how much it seams and wobbles is impressive
Remember also the relationship we have fostered with Keith Flaherty was based on data from the SCIB1 mono trial here in the U.K. So just another reason why I am not too disappointed with pulling the U,S arm at the moment.
so the past ...
well that is ichor and the FDA ... getting there act together ...
once that's sorted ..
Its price sensitive .. opens up the US trial centers with a fresh IND
Now that is an interesting view. I have posed that question a few times on here and nobody has answered it. I understand dredging up the past too when going forward is all that matters, but if we are evr going to get to a stage 3 then we need Ichors Tri-Grid and it is that need that I have never liked, or I guess some possible suitors in the past.
FWIW I think that Ichor have been selling down their stake the last few months. I was just calculating the 50k, 100k and 150k sells, which have been regular and placed with a broker and it must add up to around 5/6 million shares. That is only my opinion, but it was based on a souring of our relationship with them, confirmed in March I believe with the deal they signed with AZ.
Cricket!!! That would never have kept you away 4 years ago!!
this is my problem ...
the past .... that is in the Shareprice ... its the Future that is going to move it ..
Trial is starting ....
so why do i want to understand the past mistakes of the regulatory system or an explanation why .. will it help the future ? .. no
what it highlights is ... Ichor has lead us up the garden path .. promising the TRIGrid 2 .. Scancell has clearly understood that, which isone of the reasons why they moved to Nano vesicle ..
but they could not do that with SCIB1 .. it would invalidate the existing data , and clearly time spent with the FDA has created a Boris Moment ... we are leaving .. !! can't negotiate with you guys
but scancell is not going to talk down Ichor in public . that would not happen because of existing NDA etc
Ha ha, no, nor do I, but I do want to mention better communication. I know most of the reasons why we can"t, but I have a few examples where we can. This is whole SCIB1 trial news, delays and what has been said is just one, and can you explain why they would link the IND Approval to the U.K. arm start. Doesn"t make much sense to me?
do i want to listen to 20 mins of questions about Funding ...
Cricket ....
Anyway, are you going to the AGM??
Not really. Don"t you think "First Patients Dosed" could effect the SP??
i know .... but an RNS is not about "public relations" ... its about giving the market information that could effect the SP ..
so the "out of date " scib1 ... RNS ... was not a Public relation exercise ..
see my point ?
Inanaco, I know PR and Human Relations are not your best assets, but believe me from a PR point of view it makes a lotta sense. LOL.
Night buddy
and i was just pointing out that ""reach RNS"" exists which is not an RNS ... because the market has been informed its a Go
ie No Regulatory impediment which is the only thing that has the ability to be price sensitive in this situation ..
Inanaco, exactly anything is possible, and as Konar just said from a PR perspective it would go down well. i.e. first patient dosing.
Crikey over 12 posts just because someone reckons we will get news of dosing before AGM!!!!!!